ArticleClinical and experimental medicine2025
Integrated bioinformatics decoding of the MASLD ceRNA network reveals novel therapeutic targets.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease worldwide. The mechanisms of liver injury in MASLD patients remain incompletely elucidated. This study aims to identify novel critical genes associated with MASLD using bioinformatics approaches. Microarray datasets were downloaded from the GEO database, and differentially expressed genes (DEGs) were identified. We performed enrichment analyses, constructed protein-protein interaction (PPI) networks, and visualized co-expression networks between mRNAs and miRNAs. Hub gene expression was validated using an independent dataset, and ROC curves were generated. Subsequent analyses included clinical correlation assessments and ceRNA network construction. Enrichment analyses revealed that the cell cycle, cytokine-cytokine receptor interactions, cellular senescence, oocyte meiosis, chemokine signaling pathways, viral protein-cytokine interactions, luteinizing hormone-mediated oocyte maturation, PPAR signaling, and p53 signaling pathways were significantly enriched. Three key genes (IL1β, TLR2, and TLR4) were validated using GEO datasets. The constructed ceRNA network, comprising miRNAs, circRNAs, mRNAs, and lncRNAs, identified the hsa-miR-21-5p-TLR2and hsa-miR-34a-IL1Bpathways as critical regulators of MASLD pathogenesis. IL1B, TLR2, TLR4, CCL2, and ICAM1were identified as central genes in MASLD. The hsa-miR-21-5p-TLR2and hsa-miR-34a-IL1Bpathways are potentially associated with MASLD development, offering insights for therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.